MedKoo Cat#: 205916 | Name: PF-00337210

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PF-00337210 is an orally available ATP-competitive inhibitor of the vascular endothelial growth factor receptor type 2 (VEGFR2), with potential anti-angiogenesis and antineoplastic activities. Upon administration, the VEGFR2 tyrosine kinase inhibitor PF-00337210 selectively binds to VEGFR2 and prevents its phosphorylation which may result in an inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and may eventually cause tumor cell death. VEGFR2, a receptor tyrosine kinase, is frequently overexpressed by a variety of tumor types.

Chemical Structure

PF-00337210
PF-00337210
CAS#854514-88-8

Theoretical Analysis

MedKoo Cat#: 205916

Name: PF-00337210

CAS#: 854514-88-8

Chemical Formula: C26H27N3O5

Exact Mass: 461.1951

Molecular Weight: 461.51

Elemental Analysis: C, 67.66; H, 5.90; N, 9.10; O, 17.33

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
PF00337210; PF 00337210; PF-00337210; P337210; PF-337210; PF337210.
IUPAC/Chemical Name
N,2-dimethyl-6-((7-(2-morpholinoethoxy)quinolin-4-yl)oxy)benzofuran-3-carboxamide
InChi Key
LGXVKMDGSIWEHL-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H27N3O5/c1-17-25(26(30)27-2)21-6-4-19(16-24(21)33-17)34-23-7-8-28-22-15-18(3-5-20(22)23)32-14-11-29-9-12-31-13-10-29/h3-8,15-16H,9-14H2,1-2H3,(H,27,30)
SMILES Code
O=C(C1=C(C)OC2=CC(OC3=CC=NC4=CC(OCCN5CCOCC5)=CC=C34)=CC=C12)NC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not soluble in water.
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
PF-00337210 is a highly potent and selective ATP-competitive inhibitor of VEGFR2 TK with a cellular IC50 of 0.8 nM. In vivo, it inhibits tumor angiogenesis and human xenograft growth. Modulation of blood pressure (BP) and vascular permeability (volume transfer constant: Ktrans) appear to be suitable markers of efficacy for VEGF/VEGFR inhibitors.  PF-00337210 is well tolerated at 6 mg BID, with profound VEGFR inhibition effects (as measured by elevated BP and a significant decrease in tumor vascular parameters by DCE-MRI). (source: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=50129).          

Preparing Stock Solutions

The following data is based on the product molecular weight 461.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
 1: Marra MT, Khamphavong P, Wisniecki P, Gukasyan HJ, Sueda K. Solution formulation development of a VEGF inhibitor for intravitreal injection. AAPS PharmSciTech. 2011 Mar;12(1):362-71. Epub 2011 Feb 11. PubMed PMID: 21312012; PubMed Central PMCID: PMC3066352.